Kronos Bio Inc (NAS:KRON)
$ 1.01 -0.07 (-6.48%) Market Cap: 60.70 Mil Enterprise Value: -60.21 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 33/100

Kronos Bio Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 13, 2021 / 05:15PM GMT
Release Date Price: $25.37 (-0.24%)
Jason Gerberry

Good day, everybody. Thank you for joining us at the Bank of America annual healthcare conference being conducted virtually this year. Jason Gerberry here, one of the biotech analysts at BofA. It is my pleasure to be introducing our next company presenter, Kronos. And so, joining us from Kronos we've got Norbert Bischofberger, CEO; Jorge DiMartino, CMO; and Charles Lin, SVP of Biology.

I am going to turn the mic over to Norbert who has got a few prepared remarks, and then we will go to the Q&A from there.

Norbert Bischofberger
Kronos Bio, Inc. - President and CEO

Yes. I would like to thank Jason, you, for hosting us, and Bank of America. It's a great pleasure to be here. I would like to just quickly introduce Kronos Bio, our Company. We were founded only about three years ago, a little bit more than three years ago, have made enormous progress, really in four areas.

Number one, we are a clinical stage company. We acquired a portfolio of SYK inhibitors and one of those lead compounds will go into a Phase 3 registrational study in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot